Epidemiology and Health

COVID-19: Original Article

COVID-19 infection and severe clinical outcomes in patients with kidney disease by vaccination status: a nationwide cohort study in Korea: Jieun Woo, Ahhyung Choi, Jaehun Jung, Ju-Young Shin; Epidemiol Health. 2024;46:e2024065. Published online July 17, 2024; DOI: https://doi.org/10.4178/epih.e2024065

2,020 View
90 Download

Abstract Summary PDF Supplementary Material: Abstract
OBJECTIVES
Patients with kidney disease have been prioritized for coronavirus disease 2019 (COVID-19) vaccination due to their susceptibility to COVID-19 infection. However, little evidence exists regarding these patients’ vulnerability to COVID-19 post-vaccination. Thus, we evaluated the risk of COVID-19 in patients with kidney disease compared to individuals without kidney disease according to vaccination status.
METHODS
A retrospective cohort study was conducted using the Korean nationwide COVID-19 registry linked with National Health Insurance Service claims data (2018-2021). Among individuals aged 12 years or older, 2 separate cohorts were constructed: a COVID-19-vaccinated cohort and an unvaccinated cohort. Within each cohort, the risk of COVID-19 infection and all-cause mortality, hospitalization, and emergency room visits within 30 days of COVID-19 infection were compared between patients with and without kidney disease. To adjust for potential confounding, we used propensity score matching. Hazard ratios (HRs) for each outcome were estimated using a Cox proportional hazard model.
RESULTS
We identified 785,390 and 836,490 individuals in the vaccinated and unvaccinated cohorts, respectively. Compared to patients without kidney disease, patients with kidney disease were at a higher risk of COVID-19 infection in both the vaccinated cohort (HR, 1.08; 95% confidence interval [CI], 1.02 to 1.16) and the unvaccinated cohort (HR, 1.09; 95% CI, 0.99 to 1.20). Likewise, patients with kidney disease generally were at higher risk for severe clinical outcomes within 30 days of COVID-19 infection. Subgroup and sensitivity analyses showed generally consistent results.
CONCLUSIONS
Our study observed excess risk of COVID-19 in patients with kidney disease, highlighting the importance of ongoing attention to these patients even post-vaccination.; Summary

Korean summary
본 연구는 신장 질환이 없는 사람과 비교하여 신장 질환이 있는 환자의 COVID-19 위험을 백신 접종 여부에 따라 평가하였습니다. 백신 접종 여부와 상관없이 신장 질환이 있는 환자는 신장 질환이 없는 환자에 비해 코로나19 감염 및 코로나19 감염 이후 사망, 입원, 응급실 방문의 위험이 더 높았습니다. 즉, 이러한 연구 결과는 백신 접종 후에도 신장 질환이 있는 환자에 대한 코로나19에 대한 지속적인 주의가 필요함을 시사합니다.

Key Message
This study evaluated the risk of COVID-19 in patients with kidney disease compared to patients without kidney disease according to vaccination status. Compared to patients without kidney disease, patients with kidney disease were at a higher risk of COVID-19 infection and severe clinical outcomes after COVID-19 infection in both the vaccinated cohort and the unvaccinated cohort. These findings highlighted the importance of ongoing attention to these patients even post-vaccination.

Review

Studies on the Association between Phenylpropanolamine (PPA) and Hemorrhagic Stroke in Other Countries.: Seung Mi Lee, Byung Woo Yoon, Byung Joo Park; Korean J Epidemiol. 2004;26(2):1-7.

6,638 View
45 Download

Abstract PDF: Abstract
OBJECTIVES
Phenylpropanolamine (PPA) had been used widely as cold remedies or appetite suppressants. However, products containing PPA were withdrawn in sequence in the US, Japan, and Korea due to the increased risk of hemorrhagic stroke. The purpose of this paper was to review safety issues related with the PPA use and hemorrhagic stroke in view of pharmacoepidemiology and pharmacovigilance.
METHODS
AND MATERIALS: Researches conducted for evaluating the association between the PPA use and hemorrhagic stroke in other countries were reviewed, which involved case reports, case series, case-control studies, and cohort studies.
RESULTS
In terms of pharmacologic and clinical features, PPA may increase the risk of hemorrhagic stroke through increased blood pressure, heart rate, or vasculitis. The association between the PPA use and hemorrhagic stroke among young women was suggested by case reports from spontaneous adverse events reporting systems or medical journals. The cohort study, using the large prescription database in the US and published in 1984, failed to reveal the association in the population aged below 65. The case-control study conducted as the Yale Hemorrhagic Stroke Project, published in 2000, was the first study to find the association between the PPA as appetite suppressants and hemorrhagic stroke among women ages 18-49 years by well-designed analytic epidemiological research. It led to withdrawal of all products containing PPA in the US and many other countries since 2000. However, the association between PPA and cerebral hemorrhage could not be confirmed by the case-control study conducted in Mexico due to inappropriate recruitment of control group.
CONCLUSIONS
During several years case reports have suggested that hemorrhagic stroke could be induced by PPA, and the Yale Hemorrhagic Stroke Project revealed the association by case-control study and provided a useful model for pharmacovigilance. Nevertheless, their finding could not be applied to other population such as elderly women and male population. And they could not provide any evidence on the association between PPA and stroke when PPA was used as cold remedy taken daily dose below 100mg.; Summary

First
Prev
Page of 1
Next
Last

Search